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Membrane-associated estrogen receptor “G protein-coupled receptor 30” (GPR30) has been implicated in
spatial recognition memory and protection against neuronal death. The present study investigated the
role of GPR30 in object recognition memory in an Alzheimer's disease (AD) mouse model (5XFAD) by
using novel object recognition (NOR) test. Impairment of long-term (24 h) recognition memory was
observed in both male and female 5XFAD mice. Selective GPR30 agonist, G-1, ameliorated this impair-
ment in female 5XFAD mice, but not in male mice. Our study demonstrated the ameliorative role of
GPR30 in NOR memory impaired by AD pathology in female mice.
© 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).A novel membrane-associated estrogen receptor GPR30 medi-
ates the rapid effects of estradiol (1) probably via intracellular
signaling pathways linked to growth factor receptors, followed by
extracellular signal-regulated kinase (ERK)1/2 activation (2) and
acetylcholine release (3). Selective agonist for GPR30, G-1 can
differentiate the functions of GPR30 from the classical estrogen
receptors, establishing GPR30's role in exerting an antidepressant
effect and protection against neuronal death in the hippocampus
(2,4). The enhancing effect of G-1 on spatial recognition memory
has been demonstrated recently in the Y-maze task in ovariecto-
mized rat (5). The results of the study suggested that the activation
of GPR30 besides classical estrogen receptors is sufﬁcient to
enhance spatial memory. Previous studies demonstrated the
ameliorative effects of GPR30 activation on memory function and
neurodegeneration in an ovariectomized model or ischemic model.
However, the effect of brain GPR30 activation on memory function
in mouse models of Alzheimer's disease (AD), wherein the major
symptom is the impairment of learning and memory, remains to be
elucidated.
The present study investigates the effect of GPR30 activation on
object recognitionmemory by using novel object recognition (NOR): þ81 87 894 0181.
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d/4.0/).test in AD mouse models. For studying the effect of GPR30 activa-
tion, it is important to avoid exposing the animals to stress to
prevent unexpected facilitation of estrogen production. NOR test is
carried out under conditions that do not cause intensive stress,
which would be inevitable in the other tests involving water
exposure or fasting. NOR test mainly involves the prefrontal cortex
and hippocampus, which express GPR30 abundantly. This study
was designed to determine the role of GPR30 in short- and long-
term object recognition memory by using 5XFAD mice as a model
of AD. Most of the transgenic micewith familial ADmutations often
fail to exhibit pronounced neuron loss although they have suc-
ceeded in mimicking the extensive amyloid plaque pathology seen
in clinical AD. 5XFAD mouse is unique in displaying obvious neu-
rodegeneration along with deposition of amyloid plaque (6) and
therefore, is a useful model for studying memory dysfunctions
associated with neurodegeneration in AD. We provide the ﬁrst
evidence for the ameliorative effect of GPR30 signaling on cognitive
impairment in AD mouse models, which show Ab-related neuron
loss.
Eight-to ten-month-old male and female B6SJL-Tg (APPSwFILon,
PSEN1*M146L*L286V) 6799Vas/J (5XFAD) mice (The Jackson Lab-
oratory, Bar Harbor, USA) and age-matched non-transgenic wild
type (WT) littermates were used in this study. Mice were housed
four per cage at the maximum, and were maintained in a temper-
ature- and light-controlled environment with a 12-h light/dark
cycle (lights on at 8:00 a.m.) with free access to food and water. Allnese Pharmacological Society. This is an open access article under the CC BY-NC-ND
T. Kubota et al. / Journal of Pharmacological Sciences 131 (2016) 219e222220procedures were carried out according to the guidelines estab-
lished by the Institutional Animal Investigation Committee at the
Tokushima Bunri University. Selective GPR30 agonist G-1 (Tocris
Bioscience, Bristol, UK) was diluted to 1.0 mM with 10% dimethyl
sulfoxide (DMSO)-containing saline. Selective GPR30 antagonist G-
15 (Tocris Bioscience) was diluted to 10 mM with 10% DMSO-
containing saline. Both G-1 and G-15 solutions (0.1 ml per
mouse) were administered intraperitoneally 30 min before the
onset of each trial. The doses of G-1 and G-15 were selected based
on the previous study reported by Dennis et al (4). In the NOR test,
vehicle-treated non-transgenic littermate mice were used as a
control group. The NOR test was carried out as described in Fig. 1.
The ratio of time required to explore novel object versus that
required for familiar object was measured. Total RNA from the
prefrontal cortex (PFC) and hippocampus was isolated using the
Get pureRNA kit (Dojindo, Kumamoto, Japan) according to the
manufacturer's instructions. RT-PCR was performed using Super-
Script III First-Strand Synthesis SuperMix (Invitrogen, California,
USA) and speciﬁc primers for GPR30 and GAPDH. Statistical sig-
niﬁcance for NOR was determined by two-way ANOVA followed by
TukeyeKramer post hoc test.
Vehicle-treated WT (n ¼ 9) and 5XFAD male mice (n ¼ 5) had
similar exploratory ratio (a chance level) in the sample trial. G-1-
treated group (WT: n ¼ 4, 5XFAD: n ¼ 6) and G-1 þ G-15-treated
group (n ¼ 4) also showed similar exploration ratio (Fig. 2A). In
T1 (Fig. 2B), both vehicle-treated WT mice and 5XFAD mice spent
longer time in exploring the novel object, showing an increased
exploratory ratio (WT: 70.8 ± 2.1%, 5XFAD: 64.0 ± 2.8%), and G-1-
treated group and G-1 þ G-15-treated group also showed similar
exploration ratios (64.0 ± 5.0% and 58.1 ± 4.5%, respectively). There
was no signiﬁcant difference among these groups. In T2 (Fig. 2C),
vehicle-treated 5XFAD mice failed to identify the novel objects,
spending equal amount of time exploring both novel and familiar
objects, whereas vehicle-treated WT mice retained the object
memory (WT: 61.3 ± 3.9%, 5XFAD: 48.0 ± 3.0%). Vehicle-treatedWT
(n¼ 5) and 5XFAD femalemice (n¼ 6) had similar exploratory ratio
in the sample trial as shown in Fig. 2D. G-1-treated WT mice
(n ¼ 4), 5XFAD mice (n ¼ 8), and G-1 and G-15 co-treated 5XFAD
mice (n¼ 4) also showed similar exploration ratio and there was no
signiﬁcant difference among these groups (Fig. 2D). In T1 (Fig. 2E),
all groups of mice spent more time exploring the novel object than
familiar object (WT: vehicle 69.8 ± 2.7%, G-1 69.4 ± 3.8%, 5XFAD:
vehicle 61.6 ± 3.8%, G-1 68.2 ± 2.3%, G-1 þ G-15 70.9 ± 4.6%). There
was no signiﬁcant difference among these groups. Thus, female
5XFAD mice retained short-term object recognition memory, and
G-1 and G-15 had no effect. In T2 (Fig. 2F), vehicle-treated 5XFAD
mice failed to discriminate the novel objects, and showedFig. 1. Experimental schedule for the novel object recognition test. The study consisted of t
(T1) and twenty-four hours (T2) after the sample trial. In the NOR task, mice were placed in
explore the two objects for 10 min. Object exploration was deﬁned as snifﬁng or touching th
a 2 h and 24 h delay, mice were allowed to explore two objects, one identical to the familsigniﬁcantly lower exploratory ratio than the vehicle-treated WT
mice (49.5 ± 3.9, p < 0.05). Since the exploratory ratio was about
50%, a chance level, female 5XFADmicemight have impaired object
recognition memory as compared with WT mice. Decrement of
exploratory ratio was ameliorated by treatment with G-1
(61.4 ± 3.5, p < 0.05 vs. vehicle-treated 5XFAD mice) and this effect
was antagonized by co-administration of G-1 and G-15 (48.6 ± 6.0,
p < 0.05 vs. G-1-treated 5XFAD mice), thus indicating that GPR30 is
involved in this function. G-1 did not have any effect on exploratory
ratio inWTmice (vehicle 61.4 ± 2.7, G-1: 60.1 ± 2.6). No sex-speciﬁc
difference was observed in GPR30 mRNA expression in the PFC or
hippocampus, either in WT or in 5XFAD mice (Fig. 3).
Since both male and female 5XFADmice showed a small but not
signiﬁcantly lower exploratory ratio than WT mice in T1, 5XFAD
mice may have short-term retention of object recognition memory
during these ages. In contrast, long-term retention of object
recognition memory was impaired in both male and female 5XFAD
mice. In concordance with this data, decrease of exploratory ratio
with twenty four hours retention interval has been reported using
another line of AD mouse model, which expresses excessive Ab
deposition (7). In 5XFADmice, synaptic degeneration begins at four
months of age and obvious neurodegeneration was observed at
nine months of age (6). Deposition of Ab plaques was also observed
from the age of four months (6). Although a sex-speciﬁc difference
was not observed in the expression of GPR30 in 5XFAD mice, the
ameliorative effect of G-1 on the long-term retention of recognition
memory was observed only in female 5XFADmice. Epidemiological
studies have reported that estrogen replacement therapy has a
protective effect on cognitive function, and reduces the risk of AD in
postmenopausal females (8). However, similar ﬁndings have not
been reported in males. Abraham et al. (9) reported that estrogen
increases the phosphorylation of cyclic AMP response element-
binding protein (CREB) via a non-genomic pathway in
gonadotropin-releasing hormone (GnRH)-positive neurons in fe-
male but not male mice. Ramsden et al. (10) demonstrated that
treatment of orchidectomized male rats with E2, failed to prevent
Ab accumulation in the brain, whereas treatment with androgen
was found to be effective. In male AD mouse models, upregulated
endogenous testosterone was found to prevent the development of
AD-related cognitive decline, as assessed by hole-board test (11).
Taken together, androgens rather than estrogens can serve as an
important parameter in preventing AD related symptoms in male.
5XFAD female mice showed signiﬁcantly lower level of long-
term object recognition memory than the control mice; this was
ameliorated by treatment with G-1. These results suggest that
impairment of long-term retention of object recognition memory
observed in 5XFAD mice was due to the disturbance of GPR30hree trials: a sample (familiarization) trial, and two test trials carried out at two hours
the home cage with two objects placed on either side of the cage, and were allowed to
e object with either the nose or forepaw but not sitting or standing on the objects. After
iarization object in the sample trial and a novel object, for 10 min.
Fig. 2. Effect of GPR30 on short-term and long-term object recognition memory in male and female 5XFAD mice. In male mice, all groups exhibited a similar exploratory ratio of
around 50% in the sample trial (A). In test trials conducted 2 h after the sample trial (T1), both vehicle-treated WT mice and 5XFAD mice spent more time exploring the novel object,
showing an increased exploratory ratio (WT: 70.8 ± 2.1%, 5XFAD: 64.0 ± 2.8%). The G-1-treated group and G-1 þ G-15-treated group also showed similar exploratory ratios (WT G-1:
67.0 ± 2.1%, 5XFAD G-1: 64.0 ± 5.0%, 5XFAD G-1 þ G-15: 58.1 ± 4.5%). There was no signiﬁcant difference between these groups (B). In test trials 24 h after the sample trials (T2),
both vehicle-treated WT mice and 5XFAD mice failed to discriminate the novel objects, and spent time equally with the novel and familiar objects (WT: 61.3 ± 3.9%, 5XFAD:
48.0 ± 3.0%). G-1 and G-15 treatment had no effect on the exploratory ratio in any group (WT G-1: 58.4 ± 5.3%, 5XFAD G-1: 55.9 ± 2.3%, 5XFAD G-1 þ G-15: 51.4 ± 5.6%) (C). In
female mice, all groups of mice exhibited similar exploratory ratios of around 50% in the sample trial (D). In T1, all groups of mice spent more time exploring the novel object than
the familiar one, showing an increased exploratory ratio (WT: vehicle 69.8 ± 2.7%, G-1 69.4 ± 3.8%, 5XFAD: vehicle 61.6 ± 3.8%, G-1 68.2 ± 2.3%, G-1 þ G-15 70.9 ± 4.6%). There was
no signiﬁcant difference between these groups (E). In trial 2 at 24 h (T2), there was no effect on the exploratory ratio after treatment with G-1 in WT mice (vehicle 61.4 ± 2.7%, G-1:
60.1 ± 2.6%). Vehicle-treated 5XFAD mice failed to discriminate the novel object, showing a signiﬁcantly lower exploratory ratio when compared with vehicle-treated WT mice
(49.5 ± 3.9%, p < 0.05). This decrease in the exploratory ratio was ameliorated by treatment with G-1 (61.4 ± 3.5%, p < 0.05 vs. vehicle-treated 5XFAD mice), and was antagonized by
the co-administration of G-1 and G-15 (48.6 ± 6.0%, p < 0.05 vs. G-1-treated 5XFAD mice) (F).
Fig. 3. Level of GPR30 mRNA expression in 5XFAD mice brain. Each graph shows the percentage of GPR30 mRNA level normalized to the GAPDH mRNA level (n ¼ 3e4). In the
prefrontal cortex (PFC), there was no signiﬁcant difference in the normalized fold expression of GPR30 mRNA (WT male: 74.1 ± 6.5%, WT female 69.3 ± 3.9%, 5XFAD male:
67.3 ± 4.0%, 5XFAD female: 76.8 ± 6.1%) (A). In the hippocampus, there was no signiﬁcant difference in the expression of GPR30 mRNA (WT male: 84.4 ± 7.5%, WT female
78.9 ± 2.9%, 5XFAD male: 84.8 ± 5.7%, 5XFAD female: 77.6 ± 3.8%) (B).
T. Kubota et al. / Journal of Pharmacological Sciences 131 (2016) 219e222 221signaling. Yang et al. (12) demonstrated that stimulation of mem-
brane ER including GPR30 by treatment with membrane-
impermeable BSA-conjugated E2 enhances phosphorylation of cy-
clic CREB through activation of ERK and Akt. Non-genomic rapid
reaction of estrogen has also been reported, in that estrogen en-
hances long-term potentiation (LTP) in the hippocampus in thirty
minutes (13). G-1 rapidly induces brain-derived neurotrophicfactor (BDNF) release, which is one of the major transcriptional
targets of CREB, leading to transient synaptic plasticity in the CA3
region of the hippocampus (14). Hammond et al. (15) showed that
G-1 activates GPR30 receptor signaling and enhances the rate of
acquisition in spatial learning task. Taken together, the upregula-
tion of CREB-BDNF pathway may lead to the amelioration of object
recognition memory, which is impaired in AD mouse models.
T. Kubota et al. / Journal of Pharmacological Sciences 131 (2016) 219e222222In conclusion, we provided new evidence on the ameliorative
effect of GPR30 agonist, G-1, on long-term retention of object
recognition memory in female 5XFAD mice but not in male mice.
These results provide a new insight into the role of GPR30 in
memory function in AD.Conﬂicts of interest
The authors declare that they have no conﬂicts of interest in this
research.References
(1) Genazzani AR, Pluchino N, Luisi S, Luisi M. Estrogen, cognition and female
ageing. Hum Reprod Update. 2007;13:175e187.
(2) Tang H, Zhang Q, Yang L, Dong Y, Khan M, Yang F, et al. GPR30 mediates
estrogen rapid signaling and neuroprotection. Mol Cell Endocrinol. 2014;387:
52e58.
(3) Hammond R, Nelson D, Gibbs RB. GPR30 co-localizes with cholinergic neu-
rons in the basal forebrain and enhances potassium-stimulated acetylcho-
line release in the hippocampus. Psychoneuroendocrinology. 2011;36:
182e192.
(4) Dennis MK, Burai R, Ramesh C, Petrie WK, Alcon SN, Nayak TK, et al. In vivo
effects of a GPR30 antagonist. Nat Chem Biol. 2009;5:421e427.
(5) Hawley WR, Grissom EM, Moody NM, Dohanich GP, Vasudevan N. Activation
of G-protein-coupled receptor 30 is sufﬁcient to enhance spatial recognition
memory in ovariectomized rats. Behav Brain Res. 2014;262:68e73.(6) Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, et al. Intraneuronal beta-
amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice
with ﬁve familial Alzheimer's disease mutations: potential factors in amyloid
plaque formation. J Neurosci. 2006;26:10129e10140.
(7) Taglialatela G, Hogan D, Zhang WR, Dineley KT. Intermediate- and long-term
recognition memory deﬁcits in Tg2576 mice are reversed with acute calci-
neurin inhibition. Behav Brain Res. 2009;200:95e99.
(8) Shuster LT, Rhodes DJ, Gostout BS, Grossardt BR, Rocca WA. Premature
menopause or early menopause: long-term health consequences. Maturitas.
2010;65:161e166.
(9) Abraham IM, Herbison AE. Major sex differences in non-genomic estrogen
actions on intracellular signaling in mouse brain in vivo. Neuroscience.
2005;131:945e951.
(10) Ramsden M, Nyborg AC, Murphy MP, Chang L, Stanczyk FZ, Golde TE, et al.
Androgens modulate beta-amyloid levels in male rat brain. J Neurochem.
2003;87:1052e1055.
(11) McAllister C, Long J, Bowers A, Walker A, Cao P, Honda S, et al. Genetic tar-
geting aromatase in male amyloid precursor protein transgenic mice down-
regulates beta-secretase (BACE1) and prevents Alzheimer-like pathology
and cognitive impairment. J Neurosci. 2010;30:7326e7334.
(12) Yang LC, Zhang QG, Zhou CF, Yang F, Zhang YD, Wang RM, et al. Extranuclear
estrogen receptors mediate the neuroprotective effects of estrogen in the rat
hippocampus. PLoS One. 2010;5:e9851.
(13) Foy MR, Baudry M, Diaz Brinton R, Thompson RF. Estrogen and hippocampal
plasticity in rodent models. J Alzheimers Dis. 2008;15:589e603.
(14) Briz V, Liu Y, Zhu G, Bi X, Baudry M. A novel form of synaptic plasticity in ﬁeld
CA3 of hippocampus requires GPER1 activation and BDNF release. J Cell Biol.
2015;210:1225e1237.
(15) Hammond R, Mauk R, Ninaci D, Nelson D, Gibbs RB. Chronic treatment with
estrogen receptor agonists restores acquisition of a spatial learning task in
young ovariectomized rats. Horm Behav. 2009;56:309e314.
